Organon & Co. logo OGN - Organon & Co.

Price: -- -- | CONSENSUS: Hold DETAILS
STRONG
BUY 0
BUY 2
HOLD 4
SELL 3
STRONG
SELL 0
| PRICE TARGET: $11.33 DETAILS
HIGH: $14.00
LOW: $8.00
MEDIAN: $12.00
CONSENSUS: $11.33
DOWNSIDE: 15.64%

Stock News

Hanmi Pharmaceutical Partners with Organon to Export Combination Therapies to Southeast Asia

Hanmi Pharmaceutical Partners with Organon to Export Combination Therapies to Southeast Asia

Shin Hae-gon (right), Head of Overseas Sales at Hanmi Pharmaceutical, and Andreas Daugaard Jørgensen (left), Managing Director, Organon Asia Pacific Cluster, met at Organon's Malaysia office to discuss the expansion of Hanmi's combination therapies into the Southeast Asian market. SEOUL, South Korea, May 21, 2026 (GLOBE NEWSWIRE) -- Hanmi Pharmaceutical announced that it has signed a supply agreement with global healthcare company Organon to export three combination medicines for the Malaysian and Philippine markets, expanding the companies' partnership in Southeast Asia.

May 21, 2026 01:06 AM • globenewswire.com
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: XOMA Royalty Corporation (Nasdaq – XOMA), Organon & Co. (NYSE – OGN), RE/MAX Holdings, Inc. (NYSE – RMAX), Soleno Therapeutics, Inc. (Nasdaq – SLNO)

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: XOMA Royalty Corporation (Nasdaq – XOMA), Organon & Co. (NYSE – OGN), RE/MAX Holdings, Inc. (NYSE – RMAX), Soleno Therapeutics, Inc. (Nasdaq – SLNO)

BALA CYNWYD, Pa. , May 05, 2026 (GLOBE NEWSWIRE) -- Brodsky and Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith. com) or Marc Ackerman (mackerman@brodskysmith. com) at 855-576-4847.

May 05, 2026 10:33 AM • globenewswire.com
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger—OGN, MMTX, VRE, and ESQ

$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger—OGN, MMTX, VRE, and ESQ

NEW YORK, May 05, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating

May 05, 2026 07:51 AM • globenewswire.com (Hide legal announcements)
Organon Reports Results for the First Quarter Ended March 31, 2026

Organon Reports Results for the First Quarter Ended March 31, 2026

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN) today announced its results for the first quarter ended March 31, 2026. First Quarter 2026 Revenue in $ millions   Q1 2026   Q1 2025   VPY   VPY ex-FX Women's Health   $ 389   $ 463   (16)%   (19)% General Medicines                 Biosimilars     173     141   23%   21% Established Brands     880     887   (1)%   (7)% Other (1)     18     22   (15)%   (21)% Revenue   $ 1,460   $ 1,513   (4)%   (9)%     Totals may not foot due to rounding.

Apr 30, 2026 03:30 AM • businesswire.com
Organon Cancels First Quarter Earnings Call

Organon Cancels First Quarter Earnings Call

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today that it has canceled its first quarter 2026 earnings conference call previously scheduled for May 7, 2026. The cancellation is the result of the company's April 26, 2026 announcement that it has entered into an agreement under which Sun Pharmaceutical Industries Limited will acquire Organon. Organon will issue.

Apr 29, 2026 03:30 AM • businesswire.com
Organon & Co. Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Organon & Co. - OGN

Organon & Co. Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Organon & Co. - OGN

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Organon & Co. (NYSE: OGN) to Sun Pharmaceutical Industries Limited. Under the terms of the proposed transaction, shareholders of Organon will receive $14.00 in cash for each share of Organon that they own. KSF is seeking to determine whether this consideration and the process that led to it.

Apr 28, 2026 08:36 AM • businesswire.com (Hide legal announcements)
Stock Market Today, April 27: Organon Shares Surge After Sun Pharma Agrees to Acquire Company in All Cash Deal

Stock Market Today, April 27: Organon Shares Surge After Sun Pharma Agrees to Acquire Company in All Cash Deal

Expand NYSE: OGN Organon & Co. Today's Change (16.87%) $1.90 Current Price $13.16 Key Data Points Market Cap $2.9B Day's Range $13.15 - $13.24 52wk Range $5.69 - $13.24 Volume 134M Avg Vol 5.8M Gross Margin 53.59% Dividend Yield 0.71% Organon (OGN +16.87%), a women's health therapies specialist, closed Monday at $13.16, up 16.87%. The stock is jumping after premarket news that Sun Pharmaceutical Industries agreed to acquire Organon in an all-cash deal.

Apr 27, 2026 01:34 PM • fool.com
Johnson Fistel Investigates Potential Breaches of Fiduciary Duty in Connection with the Proposed Acquisition of Organon by Sun Pharmaceutical

Johnson Fistel Investigates Potential Breaches of Fiduciary Duty in Connection with the Proposed Acquisition of Organon by Sun Pharmaceutical

SAN DIEGO, April 27, 2026 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, PLLP has launched an investigation into whether the board members of Organon & Co. (NYSE: OGN) breached their fiduciary duties in connection with the proposed sale of the company to Sun Pharmaceutical.

Apr 27, 2026 07:02 AM • globenewswire.com (Hide legal announcements)
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Organon & Co. (NYSE: OGN)

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Organon & Co. (NYSE: OGN)

NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney  Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Organon & Co. (NYSE:  OGN ) related to its sale to Sun Pharmaceuticals Industries Limited. Under the terms of the proposed transaction, Organon shareholders will receive $14.00 per share in cash. Is it a fair deal?

Apr 27, 2026 06:43 AM • globenewswire.com (Hide legal announcements)

Price Targets